Stock Worth Mentioning Today: Edwards Lifesciences Corp Just Recorded A Sigfniciant Decline

Stock Worth Mentioning Today: Edwards Lifesciences Corp Just Recorded A Sigfniciant Decline

The stock of Edwards Lifesciences Corp (NYSE:EW) is a huge mover today! About 1.14 million shares traded hands or 14.45% up from the average. Edwards Lifesciences Corp (NYSE:EW) has risen 35.41% since March 11, 2016 and is uptrending. It has outperformed by 29.95% the S&P500.
The move comes after 9 months negative chart setup for the $24.91 billion company. It was reported on Oct, 14 by We have $110.69 PT which if reached, will make NYSE:EW worth $1.25 billion less.

Analysts await Edwards Lifesciences Corp (NYSE:EW) to report earnings on October, 24. They expect $0.67 EPS, up 24.07% or $0.13 from last year’s $0.54 per share. EW’s profit will be $143.23M for 43.48 P/E if the $0.67 EPS becomes a reality. After $0.76 actual EPS reported by Edwards Lifesciences Corp for the previous quarter, Wall Street now forecasts -11.84% negative EPS growth.

Edwards Lifesciences Corp (NYSE:EW) Ratings Coverage

Out of 25 analysts covering Edwards Lifesciences Corp (NYSE:EW), 18 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 72% are positive. Edwards Lifesciences Corp has been the topic of 49 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The rating was initiated by Cowen & Co with “Outperform” on Friday, October 9. The company was initiated on Friday, January 8 by SunTrust. The rating was maintained by SunTrust on Monday, March 7 with “Neutral”. The rating was initiated by Citigroup on Thursday, November 12 with “Sell”. Citigroup maintained it with “Sell” rating and $94 target price in Wednesday, July 27 report. The rating was upgraded by BTIG Research on Monday, April 4 to “Buy”. Canaccord Genuity maintained Edwards Lifesciences Corp (NYSE:EW) on Wednesday, February 3 with “Buy” rating. Leerink Swann maintained Edwards Lifesciences Corp (NYSE:EW) rating on Monday, April 4. Leerink Swann has “Outperform” rating and $115 price target. As per Wednesday, January 6, the company rating was reinitiated by JMP Securities. The stock has “Priority List” rating given by Wells Fargo on Monday, October 19.

According to Zacks Investment Research, “Edwards Lifesciences Corporation provides products and technologies to treat late-stage cardiovascular disease. The Company’s products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences Corporation is headquartered in Irvine, California.”

More recent Edwards Lifesciences Corp (NYSE:EW) news were published by: which released: “Edwards Lifesciences Corp stock up 2% after two heart valves approved for more …” on August 18, 2016. Also published the news titled: “Edwards Lifesciences Shares Soar on Heart-Valve Procedure Study Results” on April 04, 2016.‘s news article titled: “Edwards Lifesciences Raises 2016 View as Earnings, Revenue Top Estimates” with publication date: April 26, 2016 was also an interesting one.

EW Company Profile

Edwards Lifesciences Corporation, incorporated on September 10, 1999, is focused on technologies that treat structural heart disease and critically ill patients. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Firm conducts activities around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment